sorafenib has been researched along with n-methyladenosine in 3 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (n-methyladenosine) | Trials (n-methyladenosine) | Recent Studies (post-2010) (n-methyladenosine) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 1,470 | 3 | 1,400 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 3 (100.00) | 2.80 |
Authors | Studies |
---|---|
Bu, X; Chen, D; Chen, L; Chen, X; Cheng, C; He, W; Liang, H; Lin, Z; Niu, Y; Sun, L; Wan, A; Wan, G; Zhan, S; Zhang, X | 1 |
Cai, X; Cen, D; Gorshkov, K; Ji, L; Jiang, S; Liang, X; Lin, Z; Mao, Q; Tang, M; Wan, Z; Xia, S; Xu, J; Zheng, J | 1 |
Jiang, H; Lv, W; Ning, G; Wang, Y | 1 |
3 other study(ies) available for sorafenib and n-methyladenosine
Article | Year |
---|---|
RNA m
Topics: Adenosine; Animals; Autophagy; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Forkhead Box Protein O3; HEK293 Cells; Hep G2 Cells; Human Umbilical Vein Endothelial Cells; Humans; Liver Neoplasms; Male; Methylation; Methyltransferases; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; RNA, Messenger; RNA, Neoplasm; Sorafenib | 2020 |
N
Topics: Adenosine; Animals; Antineoplastic Agents; Apoptosis; beta Catenin; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; RNA, Circular; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
Topics: Adenosine; Biomarkers, Tumor; Carcinoma, Hepatocellular; Databases, Genetic; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Male; Neoplasm Staging; Prognosis; Sorafenib; Treatment Outcome | 2021 |